MGB
PLRX icon

Mass General Brigham’s Pliant Therapeutics PLRX Stock Holding History

Mass General Brigham’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$3.24M Hold
288,690
– – 7.42% 3
2024
Q2 		$3.1M Hold
288,690
– – 15.11% 2
2024
Q1 		$4.3M Buy
+288,690
New +$4.76M 7.53% 3

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Mass General Brigham's PLRX Position: Q3 2024 in Review

Mass General Brigham held its Pliant Therapeutics (PLRX) position steady in Q3 2024 at 288,690 shares worth $3.24M. The position accounts for 7.42% of the portfolio, ranked #3.

Mass General Brigham first reported a position in PLRX in Q1 2024 and has held it in 3 quarters since. The position peaked at $4.3M in Q1 2024. 151 funds tracked by Wall St. Rank hold PLRX as of Q3 2024.

  • Mass General Brigham held 288,690 shares of Pliant Therapeutics worth $3.24M as of Q3 2024.
  • Mass General Brigham left its Pliant Therapeutics share count unchanged in Q3 2024.
  • Pliant Therapeutics made up 7.42% of Mass General Brigham's portfolio in Q3 2024, its #3 holding.
  • Mass General Brigham first reported a position in Pliant Therapeutics in Q1 2024 and has held it in 3 quarters since.
  • Mass General Brigham's Pliant Therapeutics position peaked at $4.3M in Q1 2024.
  • 151 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2024.

Based on Mass General Brigham's 13F filing for Q3 2024, filed 16 Oct 2024.